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Abstract
Prostate cancer is the most commonly diagnosed cancer in men and one of the leading causes of
cancer deaths. There is strong genetic evidence indicating that a large proportion of prostate
cancers are caused by heritable factors but the search for prostate cancer susceptibility genes has
thus far remained elusive. TGFBR1*6A, a common hypomorphic variant of the type I Transforming
Growth Factor Beta receptor, is emerging as a tumor susceptibility allele that predisposes to the
development of breast, colon and ovarian cancer. The association with prostate cancer has not yet
been explored. A total of 907 cases and controls from New York City were genotyped to test the
hypothesis that TGFBR1*6A may contribute to the development of prostate cancer. TGFBR1*6A
allelic frequency among cases (0.086) was slightly higher than among controls (0.080) but the
differences in TGFBR1*6A genotype distribution between cases and controls did not reach
statistical significance (p = 0.67). Our data suggest that TGFBR1*6A does not contribute to the
development of prostate cancer.
Background
Transforming Growth Factor Beta (TGF-ß) is one of the
most potent inhibitor of cell growth [1]. Almost all cancer
cells loose the ability to be growth inhibited by TGF-ß,
which makes loss of TGF-ß growth inhibition a hallmark
of cancer development [2]. TGFBR1*6A is a common var-
iant of the type I TGF-ß receptor, TGFBR1 [3]. TGFBR1*6A
(*6A) has a deletion of three GCG triplets coding for
alanine within a nine alanine (9A) repeat sequence of
TGFBR1  (*9A) exon 1, resulting in a six alanine (6A)
repeat sequence. The 9-bp deletion that differentiates *6A
from *9A is located within the predicted signal sequence
cleavage region. In vitro studies have demonstrated that
TGFBR1*6A responds less effectively than TGFBR1 to
TGF-ß growth inhibitory signals [4,5]. The additional
findings of an overrepresentation of TGFBR1*6A hetero-
zygotes and homozygotes among patients with a diagno-
sis of cancer as compared with the general population led
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us to postulate that TGFBR1*6A might act as a tumor sus-
ceptibility allele [5]. Two recent meta-analyses show that
TGFBR1*6A carriers may have an increased risk of breast,
colon and ovarian cancer [6,7]. To test the hypothesis that
TGFBR1*6A may contribute to the development of pros-
tate cancer, we conducted a case control study of patients
with biopsy verified prostate cancer cases and geographi-
cally and ethnic-status matched controls.
Results
A total of 907 cases and controls were genotyped for
TGFBR1*6A. The mean age of cases was significantly
higher than controls (p < 0.01) but there were no differ-
ences in ethnic status between the two groups. There were
59  TGFBR1*6A heterozygotes and three TGFBR1*6A
homozygotes among cases, 62 TGFBR1*6A heterozygotes
and 1 TGFBR1*6A homozygote among controls.
TGFBR1*6A allelic frequency among cases (0.086) was
slightly higher than among controls (0.080) but the dif-
ferences in TGFBR1*6A genotype distribution between
cases and controls did not reach statistical significance (p
= 0.67) (Table 1). Effect estimates from conditional logis-
tic regression were similar (OR 1.01, 95% CI 0.29–3.52)
to those from unconditional logistic regression (OR 0.96,
95% CI 0.56–1.64). Analyses restricted to subjects aged 40
years and above controlling age on a continuous scale
produced essentially the same effect estimates (OR 0.94,
95% CI 0.56–1.60). To examine the possibility that
TGFBR1*6A is associated with early onset prostate cancer,
we determined the prostate cancer risk for individuals
above and below the age of 55. Among younger patients
with prostate cancer we found that 13 of 59 were
TGFBR1*6A carriers yielding an allelic frequency of 0.119,
one of the highest TGFBR1*6A allelic frequency ever
reported. Only 45 of 367 controls in the same age range
were TGFBR1*6A carriers yielding an allelic frequency of
0.063, which is similar to the TGFBR1*6A allelic fre-
quency found among 3,451 healthy controls from Europe
and the U.S. [7]. The association between carrier status of
TGFBR1*6A and prostate cancer in younger age group was
significant after adjustment for race (OR 2.13, 95% CI
1.06–4.27) but was not significant after adjustment for
race and age strata within groups (OR 2.11, 95% CI 0.98–
4.57) (Table 2). While in the older age group we did not
observe a significant association either (OR 0.57, 95% CI
0.30–1.10), the test for multiplicative interaction between
age and carrier status of TGFBR1*6A was significant (p =
0.01).
Discussion
Prostate cancer is the most common cancer and the sec-
ond most common cause of cancer death among U.S. men
[8]. A similar pattern is observed throughout the western
world. There is strong epidemiologic evidence indicating
that a large proportion of prostate cancers are caused by
heritable factors. The most convincing data is a study of
44,788 Scandinavian twins showing that 42% of prostate
Table 1: Distribution of Age, Ethnicity, and TGFBR1 Genotypes and Adjusted Odds Ratios of Prostate Cancer by TGFBR1 Genotype 
Status
Cases (N = 442) Controls (N = 465) P-value 1 Adjusted OR (95% 
CI)2
N%N%
TGFBR1 genotype
9A/9A 380 86.0 402 86.5 0.67 1.00 (ref)
9A/6A 59 13.4 62 13.3 0.96 (0.56–1.64)
6A/6A 3 0.6 1 0.2
Age
20–40 1 0.2 205 44.1 <0.01
41–60 126 28.5 204 43.9
61–80 308 69.7 55 11.8
80+ 7 1.6 1 0.2
Race
White 396 89.6 415 89.3 1.00
Black 26 5.9 29 6.3
Hispanic 8 1.8 8 1.7
Asian 2 0.5 2 0.4
Other 1 0.2 2 0.4
Unknown 9 2.0 9 1.9
1p-value for Chi-Square or Fisher's Exact Test (comparing proportions)
2 OR was adjusted for age strata and race, based on dominant model.BMC Genetics 2004, 5:28 http://www.biomedcentral.com/1471-2156/5/28
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cancer cancers may be caused by shared genes [9]. Despite
intense efforts led by several research teams, the search for
prostate cancer susceptibility genes has thus far remained
elusive. Recent studies suggest that carriers of deleterious
mutations of the BRCA2 gene have an increased prostate
cancer risk [10]. However, given the low prevalence of del-
eterious BRCA2 mutations in the general population, it is
unlikely to account for a significant proportion of prostate
cancer cases. Approximately 14% of the general popula-
tion carries at least one copy of TGFBR1*6A, which makes
it the most common candidate tumor susceptibility allele
reported to date. While there is growing evidence that
TGFBR1*6A predisposes to the development of breast,
colon and ovarian cancer, our data do not suggest that it
predisposes to the development of prostate cancer. We
have previously shown that TGFBR1*6A homozygotes
have an O.R of 2.69 and 2.02 for ovarian and colon can-
cer, respectively. The present study has the power to detect
an O.R. for prostate cancer of 1.70 or higher and therefore
rules out a major association between TGFBR1*6A and
prostate cancer. However, it does not exclude a smaller
O.R., which might have clinical relevance given the high
TGFBR1*6A allelic frequency in the general population. It
is possible that age differences in cases and controls
affected the allele frequencies observed. If the TGFBR1*6A
allele predisposes to a lethal malignancy such as prostate
cancer, however, its frequency could be higher, not lower,
in a younger cohort. Thus, the younger mean age of con-
trols could result in a bias toward the null hypothesis,
resulting in a stronger association than that observed. The
intriguing findings of a high TGFBR1*6A allelic frequency
among prostate cancer cases diagnosed before the age of
55 have to be cautiously interpreted given the fact that this
group only included 46 patients. We have previously
shown that TGFBR1*6A is not associated with an
increased risk of bladder cancer [6]. Our results suggest
that the association between TGFBR1*6A and prostate
cancer is at best very weak but further studies are needed
to formally exclude an association with early onset pros-
tate cancer.
Methods
DNA was extracted from lymphocytes of blood specimens
from 465 consecutive individuals diagnosed with adeno-
carcinoma of the prostate who received care at the outpa-
tient urology clinic at Memorial Sloan-Kettering Cancer
Center from April 2000 to September 2002. The blood
samples were collected following completion of diagnos-
tic studies. They were unselected for age or family history.
Clinical and pathological records were reviewed to con-
firm the diagnosis of prostate cancer in all subjects. Once
pathological diagnosis of prostate cancer was confirmed,
the age of diagnosis was recorded, and all other identify-
ing links were destroyed. The study design and anonymi-
zation method were approved by the Memorial Sloan-
Kettering Cancer Center Institutional Review Board.
A population of 465 healthy male controls aged 20 to 87
years with well-defined ethnic background who had
donated blood for various reasons (predominantly pre-
natal screening for non-cancer disease) constituted the
control group. Controls were matched to the cases on eth-
nicity and were from the same geographic locations as the
prostate cancer cases. None of the controls had any per-
sonal history of cancer at the time of blood donation. This
was ascertained by a questionnaire completed by each
control. Exact age information was not available for 205
controls since it was not collected prospectively but the
age range (20 to 40) was known. All personal identifiers
were permanently removed from both cases and controls.
DNA was extracted by standard technique using the Qia-
gen DNA extraction kit. The PCR primers used were 5'-
CCA CAG GCG GTG GCG GCG CGA TG-3' in the forward
direction and 5'-CGT CGC CCC CGG GAF CAG CGC
CGC-3' in the reverse direction. A standard solution was
Table 2: Adjusted Odds Ratios of prostate cancer by age groups (> 55, <= 55 years old)
Age group/ 
Genotypes
Cases N (% within age 
strata)
Controls N (% within 
age strata)
OR (95% CI)1 OR (95% CI)2 P for testing 
multiplicative 
interaction
Age = 55
9A/9A 46 (78.0) 322 (87.7) 1.00 1.00
9A/6A or 6A/6A 13 (22.0) 45 (12.3) 2.13 (1.06–4.27) 2.11 (0.98–4.57)
Age > 55 0.01
9A/9A 334 (87.2) 80 (81.6) 1.00 1.00
9A/6A or 6A/6A 49 (12.8) 18 (18.4) 0.64 (0.36–1.17) 0.57 (0.30–1.10)
1 OR was adjusted for race.
2 OR was adjusted for race and age strata within age groupsPublish with BioMed Central    and   every 
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prepared using the Clontech Advantage® GC rich kit (BD-
Biosciences Clontech, Palo Alto, CA). The PCR reaction
mixture included 20 ng of genomic DNA in a 10-µL reac-
tion volume and the following concentration of other rea-
gents: primers (0.25 µM each), 1X GC genomic PCR
reaction buffer, 1.625 mM Mg2+, 0.2 mM dNTPs and 0.16
µL of Advantage-GC genomic polymerase mix. Polymer-
ase chain reaction cycling conditions consisted of an ini-
tial denaturation period of 3 minutes at 94°C, then 35
cycles of denaturation for 30 seconds at 94°C and anneal-
ing/extension for 2 minutes at 72°C, followed by a final
extension step of 5 minutes at 72°C. Quality controls
were run on a 2% agarose gel. The ABI Prism 310 Genetic
Analyzer (Applied Biosystems, Foster City, CA) was used
for data acquisition. A peak at 115 base pairs corre-
sponded to TGFBR1 allele, whereas a peak at 107 base
pairs corresponded to the TGFBR1*6A variant. The rare
equivocal results were confirmed by cloning of the PCR
product followed by automated sequencing. Samples
were read by two independent investigators unaware of
the case /control status. Ten percent of samples were ran-
domly selected and run for quality assurance. Concord-
ance rate was 100%.
Statistical analysis
Distributions of TGFBR1  genotypes, age, and ethnicity
were compared between cases and controls using Fisher's
exact tests. To test the hypothesis that the hypomorphic
TGFBR1*6A gene is related to an increased prostate cancer
risk, adjusted odds ratios of prostate cancer were esti-
mated using both conditional and unconditional logistic
regression models. Both models were run since the
matched controls of cases with missing genotypes had to
be excluded in the conditional models but could be
included in the unconditional models. Adjusted odds
ratios of prostate cancer were estimated comparing carri-
ers of TGFBR1*6A versus non-carriers under dominant
models. Potential confounders such as age (in four strata)
and ethnicity were controlled in the analysis. Whether the
effects of TGFBR1*6A on prostate cancer differ by age was
evaluated by stratified analysis and tests for multiplicative
interaction. A small p value indicates that interaction of
age and gene is statistically significant on the multiplica-
tive level. For the unconditional models, sensitivity anal-
ysis was conducted to evaluate the impact of the fact that
the exact age of some controls with age 20–40 years is
unknown (N = 126). With 442 cases and 465 controls, the
power to detect an OR of 1.7 and 2 in the present study
was 0.86 and 0.98, respectively, based on a two-tailed test
at the 0.05 significance level.
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